Antitrypanosomal Chloronitrobenzamides
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c01680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Angela K Carrillo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States. Hauptthemen laut MEDLINE: Trypanosomiasis, African, Trypanosoma brucei brucei, Trypanocidal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: American Lebanese Syrian Associated Charities, Galvmed, St Jude Children?s Research Hospital.
Abstract (Originalsprache)
Human African trypanosomiasis (HAT), a neglected tropical disease caused by Trypanosoma brucei gambiense (Tbg) or Trypanosoma brucei rhodesiense (Tbr), remains a significant public health concern with over 55 million people at risk of infection. Current treatments for HAT face the challenges of poor efficacy, drug resistance, and toxicity. This study presents the synthesis and evaluation of chloronitrobenzamides (CNBs) against Trypanosoma species, identifying previously reported compound 52 as a potent and selective orally bioavailable antitrypanosomal agent. 52 was well tolerated in vivo and demonstrated favorable oral pharmacokinetics, maintaining plasma concentrations surpassing the cellular EC50 for over 24 h and achieving peak brain concentrations exceeding 7 μM in rodents after single oral administration (50 mg/kg). Treatment with 52 significantly extended the lifespan of mice infected with Trypanosoma congolense and T. brucei rhodesiense. These results demonstrate that 52 is a strong antitrypanosomal lead with potential for developing treatments for both human and animal African trypanosomiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536-0509, United States.
- Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Daejeon, KR 34114, United States.
- Department of Medical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Kreuzstrasse 2, Allschwil 4123, Switzerland.
- Faculty of Science, University of Basel, Petersplatz 1, Basel 4003, Switzerland.
ORCID-Profile: Jong Yeon Hwang, R Kiplin Guy
Förderung
- American Lebanese Syrian Associated Charities
- Galvmed
- St Jude Children?s Research Hospital
Zitieren
APA
Carrillo, A. K., Kadayat, T. M., Hwang, J. Y., Chen, Y., Zhu, F., Holbrook, G., Gillingwater, K., Connelly, M. C., Yang, L., Kaiser, M., & Guy, R. K. (2024). Antitrypanosomal Chloronitrobenzamides. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01680
Vancouver
Carrillo AK, Kadayat TM, Hwang JY, Chen Y, Zhu F, Holbrook G, et al. Antitrypanosomal Chloronitrobenzamides. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01680
BibTeX
@article{Carrillo2024,
author = {Carrillo, Angela K and Kadayat, Tara Man and Hwang, Jong Yeon and Chen, Yizhe and Zhu, Fangyi and Holbrook, Gloria and Gillingwater, Kirsten and Connelly, Michele C and Yang, Lei and Kaiser, Marcel and Guy, R Kiplin},
title = {Antitrypanosomal Chloronitrobenzamides},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c01680}
}
EUVIMED